Skip to main content
Explore URMC
menu

Non-Hodgkin Lymphoma: Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy

Research Question:
What is the efficacy and safety of lisocabtagene maraleucel (JCAR017) in adults who have relapsed from, or are refractory to, a single line of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL)?

Basic Study Information

Purpose:
This is a Phase 2, open-label, multicenter study to determine the efficacy and safety of lisocabtagene maraleucel (JCAR017) in adult subjects who have relapsed from, or are refractory to, a single line of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) and are ineligible for hematopoietic stem cell transplant (based on age, performance status, and/or comorbidities). Subjects will receive treatment with lisocabtagene maraleucel and will be followed for 2 years for safety, pharmacokinetics and biomarkers, disease status, quality of life, and survival.

Location: University of Rochester Medical Center
Study Reference #: IBMT19021

Lead Researcher (Principal Investigator)

Lead Researcher:  Patrick Reagan

Study Contact Information

Study Coordinator: Delaney Dretto
Phone: (585) 275-5825
Email: Delaney_Dretto@URMC.Rochester.edu

Additional Study Details

Return to Search